Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction

被引:36
|
作者
Murphy, Sean P. [1 ]
Prescott, Margaret F. [2 ]
Maisel, Alan S. [3 ]
Butler, Javed [4 ]
Pina, Ileana L. [5 ]
Felker, G. Michael [6 ,7 ]
Ward, Jonathan H. [2 ]
Williamson, Kristin M. [2 ]
Camacho, Alexander [1 ]
Kandanelly, Ritvik R. [1 ]
Solomon, Scott D. [8 ,9 ]
Januzzi, James L. [1 ,9 ,10 ]
机构
[1] Massachusetts Gen Hosp, Yawkey 5984,55 Fruit St, Boston, MA 02114 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[4] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA
[5] Detroit Med Ctr, Detroit, MI USA
[6] Duke Univ, Med Ctr, Durham, NC USA
[7] Duke Clin Res Inst, Durham, NC USA
[8] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[9] Harvard Med Sch, Boston, MA 02115 USA
[10] Baim Inst Clin Res, Boston, MA USA
关键词
biomarkers; echocardiography; heart failure; prospective studies; valsartan; SOLUBLE ST2; NATRIURETIC PEPTIDE; TROPONIN-T; PROGNOSTIC VALUE; ENALAPRIL; THERAPY;
D O I
10.1161/CIRCHEARTFAILURE.120.008410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Sacubitril/valsartan (S/V) treatment is associated with reverse cardiac remodeling and reductions in biomarkers reflecting ventricular wall stress and myocardial injury, such as NT-proBNP (N-terminal pro-B-type natriuretic peptide), hscTnT (high-sensitivity cardiac troponin T), and soluble suppressor of tumorigenicity 2 (sST2). How longitudinal changes in these biomarkers analyzed collectively are associated with cardiac remodeling in patients with heart failure with reduced ejection fraction treated with S/V is uncertain. METHODS: In a prospective study of S/V in patients with heart failure with reduced ejection fraction, this prespecified exploratory analysis included patients with serially collected biomarkers and echocardiographic measures of cardiac remodeling through 12 months of treatment. A multivariate latent growth curve model assessed associations between simultaneous changes in biomarkers and left ventricular ejection fraction and left atrial volume index. RESULTS: Seven hundred fifteen out of 794 total study participants were included (mean age 65 years, 73% male). Mean baseline left ventricular ejection fraction and left atrial volume index were 29% and 40 mL/m(2), respectively. Adjusted geometric mean baseline concentrations for biomarkers included NT-proBNP of 649 pg/mL, hs-cTnT of 15.9 ng/ L, and sST2 of 24.7 ng/mL. Following initiation of S/V, circulating concentrations of NT-proBNP, hs-cTnT, and sST2 significantly decreased within 30 days and remained significantly different than baseline at all subsequent timepoints. From baseline to month 12, decreases in adjusted biomarker concentrations averaged -27.9% (95% CI, -35.1% to -20.7%; P<0.001) for NT-proBNP; -6.7% (95% CI, -8.8% to -4.7%; P<0.001) for hs-cTnT; and -1.6% (95% CI, -2.9% to -0.4%; P<0.001) for sST2. NT-proBNP concentrations were predictive of later changes in hs-cTnT. The magnitude of reductions in NT-proBNP and hs-cTnT concentrations associated with improvements in left ventricular ejection fraction and left atrial volume index. There was no association between changes in sST2 and changes in other measures. CONCLUSIONS: Following initiation of S/V, NT-proBNP, hs-cTnT, and sST2 concentrations decreased significantly. Longitudinal changes in NT-proBNP and hs-cTnT together associated with left atrial and left ventricular reverse remodeling.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Angiotensin Receptor-neprilysin Inhibitor Therapy is Associated With Improved Echocardiographic Parameters in Chronic Heart Failure Patients With Reduced Ejection Fraction
    Poglajen, Gregor
    Drofenik, Ajda Anzic
    Jurca, Dominika
    Zemljic, Gregor
    Cerar, Andraz
    Okrajsek, Renata
    Sebestjen, Miran
    Frljak, Sabina
    Vrtovec, Bojan
    CIRCULATION, 2019, 140
  • [32] Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction
    Nasrallah, Dima
    Abdelhamid, Alaa
    Tluli, Omar
    Al-Haneedi, Yaman
    Dakik, Habib
    Eid, Ali H.
    PHARMACOLOGICAL RESEARCH, 2024, 204
  • [33] Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction
    Lee, Yu-Chien
    Lin, Joshua K.
    Ko, Darae
    Cheng, Susan
    Patorno, Elisabetta
    Glynn, Robert J.
    Tsacogianis, Theodore
    Kim, Dae Hyun
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 (10) : 3110 - 3121
  • [34] FRAILTY AND UPTAKE OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR FOR HEART FAILURE WITH REDUCED EJECTION FRACTION
    Lee, Y.
    Lin, K. J.
    Ko, D.
    Cheng, S.
    Patorno, E.
    Glynn, R. J.
    Tsacogianis, T.
    Kim, D.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 : S224 - S225
  • [35] Angiotensin Receptor Neprilysin Inhibition Improves Arterial Stiffness And Endothelial Function In Heart Failure With Reduced Ejection Fraction
    Nathaniel, Sangeetha D.
    McGinty, Shane
    Edwards, David G.
    Farquhar, William B.
    Melissa, A.
    Hosmane, Vinay
    Wenner, Megan M.
    HYPERTENSION, 2020, 76
  • [36] Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction
    Okutucu, Sercan
    Fatihoglu, Sefik Gorkem
    Sabanoglu, Cengiz
    Bursa, Nurbanu
    Sayin, Begum Yetis
    Aksoy, Hakan
    Oto, Ali
    HERZ, 2021, 46 (SUPPL 1) : 69 - 74
  • [37] Angiotensin Receptor Neprilysin Inhibition Across Ejection Fraction and Acuity Spectra in Heart Failure
    Myhre, Peder L.
    Lam, Carolyn S. P.
    JACC-HEART FAILURE, 2024, 12 (03) : 583 - 587
  • [38] Status and timing of angiotensin receptor-neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry
    Stolfo, Davide
    Benson, Lina
    Lindberg, Felix
    Dahlstrom, Ulf
    Kack, Oskar
    Sinagra, Gianfranco
    Lund, Lars H.
    Savarese, Gianluigi
    EUROPEAN JOURNAL OF HEART FAILURE, 2024,
  • [39] Getting the "Right" Perspective on Angiotensin Receptor-Neprilysin Inhibition in Heart Failure
    Verbrugge, Frederik H.
    Borlaug, Barry A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (13):
  • [40] Angiotensin receptor-neprilysin inhibition improves peak oxygen consumption in reduced heart failure patients
    Catia Ferreira, C.
    Martinho, A. S.
    Almeida, J. P.
    Freitas, A. Z.
    Ferreira, J. A.
    Domingues, C.
    Milner, J.
    Costa, S.
    Franco, F.
    Vieira, H.
    Coutinho, R.
    Baptista, R.
    Goncalves, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 237 - 237